Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2015 · 10-Q
Revenue$39.36M$39.36M+73.5% vs Q3 2014 Net Income$3.92M$3.92MN/M vs Q3 2014 EPS Diluted$0.08$0.08N/M vs Q3 2014 Operating Income$5,085,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,038,000N/M Margins · derivedOperating margin12.9%+16.2 pt vs Q3 2014
Net margin9.9%+20.4 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 9, 2015 · 40 d after period end